LakeShore Biopharma Co., Ltd. (LSB)
(Delayed Data from NSDQ)
$0.44 USD
0.00 (-0.02%)
Updated Aug 30, 2024 03:36 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LSB 0.44 0.00(-0.02%)
Will LSB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LSB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSB
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
LSB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates
Other News for LSB
YS Biopharma reports FY results
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
LakeShore Biopharma Announces Executive Reshuffle
LakeShore Biopharma Reveals Major Board Changes